InVivium Capital

Grove Biopharma is a biotechnology company dedicated to addressing unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases. It specializes in the discovery and development of a new class of protein-like polymers, utilizing artificial intelligence and precision polymer chemistry to create hybrid synthetic protein mimetics. The company also provides materials science solutions to tackle challenges associated with peptide therapeutics, thereby facilitating researchers' access to innovative drugs in critical areas of healthcare.

Hinge Bio, Inc. is a biotechnology company based in Burlingame, California, established in 2015. The company focuses on developing a novel class of bispecific and multispecific antibodies through its proprietary Flex-Hinge antibody platform. This platform utilizes advanced chemical ligation process technology, allowing the creation of therapeutic candidates that exhibit significantly enhanced affinity and specificity. Hinge Bio's approach enables these antibodies to bind cooperatively to multiple disease targets and effector cells, which can facilitate effective treatment strategies for various conditions, including oncology, metabolic diseases, and neurodegenerative disorders. The company's innovative platform aims to improve early disease diagnosis and treatment options for medical providers.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on improving mental health treatment through personalized medicine. By utilizing an AI-enabled biomarker platform, Alto integrates detailed patient data regarding brain activity and behavior to develop effective therapeutics for specific populations. The company aims to transform the traditional trial-and-error approach in psychiatry by matching the appropriate treatment to individual patients, thereby enhancing the effectiveness of interventions. Alto's clinical-stage assets include various products targeting conditions such as depressive disorders and schizophrenia, identified through independent brain-based biomarkers. Through its innovative approach, Alto Neuroscience seeks to redefine psychiatric care at a critical time for mental health.

Virtual Incision is focused on developing innovative surgical solutions, specifically through its miniaturized robotic support device designed for colon resection. The company's flagship product, the MIRA (Miniaturized In vivo Robotic Assistant) Platform, is a pioneering device that aims to streamline surgical procedures by allowing for quick setup in the operating room without the need for heavy equipment. This technology is intended to assist surgeons in improving clinical outcomes while also addressing healthcare costs. Virtual Incision's approach represents a significant advancement in robotic-assisted surgery, with plans for future applications beyond colon resection.